Answers Logo
Search

PollDaddy Answers > All Polls By This User >

Regulatory approval of New Molecular Entities (NMEs) is at a record-low pace for 2008. To what do you attribute this?



Due to safety concerns, the FDA and EMEA are being overly cautious.

Reviewers at the regulatory agencies are overworked and understaffed.

The biopharmaceutical industry is suffering from a severe lack of innovation.

None of the above.

Vote

Share/Save/Bookmark
View The Results of This Poll


See this poll in action: This poll is currently posted at this URL...
http://www.envisagemag.com/


rss

User

This user does not have a PollDaddy profile set up yet...

View My Previous Polls

Share Link

Use the link below to share this poll.

Embed This Poll

You can also place this poll on your website or blog as a widget. Simply copy and paste the code below into your HTML.

Alternatively, we now support oEmbed.